18th October 2016
US private equity firm invests in TrakCel
US private equity firm invests in leading Cellular Orchestration Platform developer, TrakCel.
TrakCel, the leading provider of cellular orchestration technology to aid in the delivery of regenerative therapies, has successfully completed a multi-million dollar investment by San Francisco-based Telegraph Hill Partners to support the company’s global growth activities.
The successful completion of the transaction, following a series of significant new contract wins in the USA and the opening of TrakCel’s US office in Newport Beach California, allows the company to further enhance its technology platform and catalyse its ambitious global growth plans.
“We believe we have found the perfect strategic partners in Telegraph Hill Partners. We are very enthusiastic about the expertise and experience that they bring,” said Ravi Nalliah, CEO of TrakCel. “The team, together with the financial support provided by this transaction, will allow TrakCel to accelerate the development of our full suite of cellular orchestration delivery technologies. TrakCel’s Cellular Orchestration Platform (COP), allied to our growing partner ecosystem, will provide our customers a powerful delivery platform to enable commercialization of both current and next generation personalized
therapies and novel treatments for many diseases.”
“THP’s growth investment in TrakCel is the result of our global search to identify and invest in companies positioned to become the leaders providing the infrastructure required to support commercially successful cell and gene therapies,” said Matt Mackowski, Chairman of THP. “Bringing decades of expertise in pharmaceutical supply chain and information technologies, TrakCel’s team is in the process of scaling up the most advanced cell therapy management system in the field.”
Concurrent with the financing, Matt Mackowski, Tom Raffin M.D., and Rob Hart, CFA from Telegraph Hill Partners, will join the company’s Board.
Find out more about TrackCel on their profile.